Biomarkers found in the blood can reveal changes in the body that may signal lung cancer before symptoms appear.

The blood test for those at high risk of lung cancer could lead to earlier detection and a "major reduction" in deaths, a ...

Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for ...

This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...

Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can ...

Oxford, UK and Toronto-based OXcan has secured over $11 million USD in Series A funding to develop and deploy its ...

Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding ...

Groundbreaking research from the University of St Andrews School of Medicine has found that biomarker testing in individuals ...

Lung cancer accounts for 21 percent of all cancer deaths in the UK, with its warning signs often not showing until the ...

Lung cancer is the most common cause of cancer death in the UK, and is usually diagnosed late. However, the condition can ...

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.